Unflame
Back to guidelines

Clinical risk follow-up

Sodium reduction and cardiometabolic risk follow-up

Sodium reduction is kept in the guideline system because it is important for blood pressure and cardiometabolic risk, not because it is a proven hsCRP or IL-6 intervention.

Last reviewed: June 14, 2026

Rank score 22
hsCRP / CRP Not a direct marker target
IL-6 Not a direct marker target
Confidence Low

Marker interpretation

This should be shown as clinical-risk follow-up, not as an anti-inflammatory biomarker promise.

Practical focus and cautions

  • Keep adult salt intake below 5 g/day, equivalent to about 2 g sodium/day.
  • Reduce high-sodium sauces, bouillon, salty snacks, processed meats, and ready meals.
  • Interpret blood pressure, glucose, lipids, weight trend, hsCRP, and symptoms together.
  • Potassium-based salt substitutes are not appropriate for everyone, especially people at risk of hyperkalaemia.
  • Sodium guidance should be individualized for kidney disease, heart failure, endurance sport, or medication constraints.
  1. NUTRITION 11

    Keep salt intake below 5 g per day, equivalent to about 2 g sodium per day for adults.

  2. NUTRITION 12

    Reduce high-sodium sauces, bouillon, salty snacks, processed meats, and ready meals.

  3. CLINICAL 01

    Review blood pressure, glucose, lipids, and weight trajectory alongside inflammation markers.

  4. CLINICAL 02

    Interpret hsCRP as a repeatable risk marker, not a diagnosis by itself.

  5. CLINICAL 03

    Delay biomarker interpretation during acute infection, injury, or recent intense exercise when possible.

  6. CLINICAL 04

    Treat IL-6 as a specialized marker whose interpretation depends strongly on timing, assay, and clinical context.

Sources